Allen Capital Group LLC Boosts Holdings in Novo Nordisk A/S $NVO

Allen Capital Group LLC raised its position in Novo Nordisk A/S (NYSE:NVO) by 29.1% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 74,191 shares of the company’s stock after buying an additional 16,727 shares during the quarter. Allen Capital Group LLC’s holdings in Novo Nordisk A/S were worth $2,727,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Godfrey Financial Associates Inc. acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter worth $25,000. Scarborough Advisors LLC purchased a new stake in shares of Novo Nordisk A/S in the first quarter valued at about $26,000. WealthCollab LLC increased its stake in shares of Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares during the period. American National Bank & Trust acquired a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $28,000. Finally, Maseco LLP purchased a new position in Novo Nordisk A/S during the fourth quarter worth about $29,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on NVO shares. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Zacks Research cut Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Friday, June 19th. Finally, Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Five analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $47.20 on Friday. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $64.16. The company has a 50-day simple moving average of $46.92 and a 200-day simple moving average of $45.50. The company has a market capitalization of $210.74 billion, a PE ratio of 11.08, a P/E/G ratio of 4.71 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The firm had revenue of $10.85 billion for the quarter. Equities research analysts predict that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk’s existing obesity business remains a key support. The company recently received European approval for a once-daily Wegovy pill and partnered with Crux to expand access to Wegovy through U.S. employer health plans, potentially broadening distribution and affordability. Novo Nordisk Teams Up With Crux To Expand Wegovy Access
• Neutral Sentiment: Some investor commentary indicates that Novo Nordisk’s current revenue drivers, particularly its GLP-1 medicines, remain intact despite the pipeline setback. However, the failed trial increases reliance on those products for future growth. NVO Stock Slumps After Late-Stage Trial Fails Primary Goal
• Negative Sentiment: In the Phase 3 ZEUS trial, ziltivekimab failed to significantly reduce major adverse cardiovascular events versus placebo in patients with cardiovascular disease, chronic kidney disease and inflammation. The result eliminates or reduces the near-term commercial potential of a drug intended to expand Novo Nordisk’s cardiovascular portfolio. Novo Nordisk’s Inflammation Drug Fails to Reduce Cardiovascular Risk in Trial
• Negative Sentiment: The setback is weighing on investor confidence in Novo Nordisk’s pipeline and has pushed the stock lower as markets reassess future growth and valuation. Novo Nordisk Shares Dive After Heart Medicine Fails Trial
• Negative Sentiment: Erste Group Bank also trimmed its fiscal 2026 earnings estimate to $3.20 per share from $3.22, below the $3.39 consensus estimate, adding to the cautious outlook. Novo Nordisk Analyst Estimate Update

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.